Articles from Walden Biosciences Securities Corporation

Walden Biosciences to Present Phase 1+ and Phase 2 Data for WAL0921 at American Society of Nephrology Kidney Week

Late-breaking poster presentation to showcase initial activity of WAL0921 in proteinuric kidney diseaseAdditional poster demonstrates WAL0921 is safe, well tolerated, and reduces circulating suPAR levels in healthy participants

By Walden Biosciences Securities Corporation · Via GlobeNewswire · October 2, 2026

Walden Biosciences Announces CMO Appointment and Upcoming Clinical Data for WAL0921 in Proteinuric Chronic Kidney Disease

Rekha Abichandani, M.D., appointed Chief Medical Officer

By Walden Biosciences Securities Corporation · Via GlobeNewswire · September 15, 2026